Operating Income (Loss) in USD of GT Biopharma, Inc. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
GT Biopharma, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q2 2010 to Q3 2025.
  • GT Biopharma, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$3.38M, a 6.16% increase year-over-year.
  • GT Biopharma, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$10.6M, a 23.1% increase year-over-year.
  • GT Biopharma, Inc. annual Operating Income (Loss) for 2024 was -$14.4M, a 5.8% decline from 2023.
  • GT Biopharma, Inc. annual Operating Income (Loss) for 2023 was -$13.6M, a 36.1% increase from 2022.
  • GT Biopharma, Inc. annual Operating Income (Loss) for 2022 was -$21.3M, a 63% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

GT Biopharma, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$10.6M -$3.38M +$222K +6.16% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$10.8M -$1.51M +$2.39M +61.3% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 -$13.2M -$1.93M +$1.16M +37.5% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 -$14.4M -$3.76M -$595K -18.8% 01 Oct 2024 31 Dec 2024 10-K 21 Feb 2025
Q3 2024 -$13.8M -$3.6M -$482K -15.4% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$13.3M -$3.91M -$285K -7.87% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 -$13M -$3.09M +$574K +15.7% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 -$13.6M -$3.17M +$2.61M +45.2% 01 Oct 2023 31 Dec 2023 10-K 21 Feb 2025
Q3 2023 -$16.2M -$3.12M +$3.9M +55.5% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$20.1M -$3.62M -$607K -20.1% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 -$19.5M -$3.67M +$1.78M +32.7% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q4 2022 -$21.3M -$5.78M +$12.4M +68.2% 01 Oct 2022 31 Dec 2022 10-K 26 Mar 2024
Q3 2022 -$33.7M -$7.02M -$1.07M -18% 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023
Q2 2022 -$32.6M -$3.01M +$1.37M +31.2% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023
Q1 2022 -$34M -$5.44M +$23.6M +81.2% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 -$57.5M -$18.2M -$13.8M -320% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023
Q3 2021 -$43.7M -$5.95M -$4.01M -206% 01 Jul 2021 30 Sep 2021 10-Q 31 Oct 2022
Q2 2021 -$39.7M -$4.38M -$2.82M -181% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 -$36.8M -$29M -$30.1M -2810% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022
Q4 2020 -$6.76M -$4.33M -$35.6M -114% 01 Oct 2020 31 Dec 2020 10-K 28 Mar 2022
Q3 2020 $28.8M -$1.95M +$6.91M +78% 01 Jul 2020 30 Sep 2020 10-Q 13 Nov 2020
Q2 2020 $21.9M -$1.56M +$721K +31.6% 01 Apr 2020 30 Jun 2020 10-Q/A 18 Aug 2020
Q1 2020 $21.2M $1.07M +$5.13M 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021
Q4 2019 $16.1M $31.2M +$34.3M 01 Oct 2019 31 Dec 2019 10-K 16 Apr 2021
Q3 2019 -$18.3M -$8.86M +$226M +96.2% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020
Q2 2019 -$244M -$2.28M +$2.88M +55.8% 01 Apr 2019 30 Jun 2019 10-Q/A 18 Aug 2020
Q1 2019 -$247M -$4.06M +$3.1M +43.4% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020
Q4 2018 -$250M -$3.09M +$2.8M +47.5% 01 Oct 2018 31 Dec 2018 10-K 27 Mar 2020
Q3 2018 -$253M -$235M -$108M -85% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019
Q2 2018 -$145M -$5.16M -$3.87M -301% 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019
Q1 2018 -$141M -$7.16M -$5.62M -366% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019
Q4 2017 -$136M -$5.89M -$5.07M -617% 01 Oct 2017 31 Dec 2017 10-K 29 Mar 2019
Q3 2017 -$131M -$127M -$124M -4914% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018
Q2 2017 -$6.18M -$1.29M +$836K +39.4% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018
Q1 2017 -$7.01M -$1.54M +$2.36M +60.6% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018
Q4 2016 -$9.37M -$822K +$2.09M +71.7% 01 Oct 2016 31 Dec 2016 10-K 01 Mar 2018
Q3 2016 -$11.5M -$2.53M +$247K +8.89% 01 Jul 2016 30 Sep 2016 10-Q/A 28 Feb 2018
Q2 2016 -$11.7M -$2.12M -$690K -48.2% 01 Apr 2016 30 Jun 2016 10-Q/A 28 Feb 2018
Q1 2016 -$11M -$3.9M -$2.09M -115% 01 Jan 2016 31 Mar 2016 10-Q/A 28 Feb 2018
Q4 2015 -$8.93M -$2.91M -$1.27M -77.1% 01 Oct 2015 31 Dec 2015 10-K/A 28 Feb 2018
Q3 2015 -$7.66M -$2.78M -$2.23M -406% 01 Jul 2015 30 Sep 2015 10-Q/A 28 Feb 2018
Q2 2015 -$5.43M -$1.43M -$1.33M -1276% 01 Apr 2015 30 Jun 2015 10-Q/A 28 Feb 2018
Q1 2015 -$4.11M -$1.81M -$1.71M -1693% 01 Jan 2015 31 Mar 2015 10-Q/A 28 Feb 2018
Q4 2014 -$2.4M -$1.64M -$1.48M -889% 01 Oct 2014 31 Dec 2014 10-K/A 28 Feb 2018
Q3 2014 -$920K -$549K -$409K -292% 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2015
Q2 2014 -$511K -$104K +$36K +25.7% 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015
Q1 2014 -$547K -$101K +$246K +70.9% 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015
Q4 2013 -$793K -$166K +$572K +77.5% 01 Oct 2013 31 Dec 2013 10-K 31 Mar 2015
Q3 2013 -$1.37M -$140K +$1.21M +89.6% 01 Jul 2013 30 Sep 2013 10-Q 17 Dec 2014
Q2 2013 -$2.58M -$140K +$890K +86.4% 01 Apr 2013 30 Jun 2013 10-Q 08 Jan 2015
Q1 2013 -$3.47M -$347K +$49K +12.4% 01 Jan 2013 31 Mar 2013 10-Q 08 Jan 2015
Q4 2012 -$3.51M -$738K +$310K +29.6% 01 Oct 2012 31 Dec 2012 10-K 08 Jan 2015
Q3 2012 -$3.82M -$1.35M -$809K -150% 01 Jul 2012 30 Sep 2012 10-Q 17 Dec 2014
Q2 2012 -$3.02M -$1.03M -$549K -114% 01 Apr 2012 30 Jun 2012 10-Q 12 Dec 2014
Q1 2012 -$2.47M -$396K +$1.46M +78.7% 01 Jan 2012 31 Mar 2012 10-Q 10 Dec 2014
Q4 2011 -$3.93M -$1.05M 01 Oct 2011 31 Dec 2011 10-K 18 Nov 2014
Q3 2011 -$541K +$113K +17.3% 01 Jul 2011 30 Sep 2011 10-Q 21 Nov 2012
Q2 2011 -$481K -$95K -24.6% 01 Apr 2011 30 Jun 2011 10-Q/A 13 Sep 2012
Q1 2011 -$1.86M 01 Jan 2011 31 Mar 2011 10-Q 21 May 2012
Q3 2010 -$654K 01 Jul 2010 30 Sep 2010 10-Q 21 Nov 2011
Q2 2010 -$386K 01 Apr 2010 30 Jun 2010 10-Q/A 12 Sep 2011

GT Biopharma, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$14.4M -$788K -5.8% 01 Jan 2024 31 Dec 2024 10-K 21 Feb 2025
2023 -$13.6M +$7.68M +36.1% 01 Jan 2023 31 Dec 2023 10-K 21 Feb 2025
2022 -$21.3M +$36.3M +63% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024
2021 -$57.5M -$50.8M -750% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
2020 -$6.76M -$22.8M -142% 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022
2019 $16.1M +$266M 01 Jan 2019 31 Dec 2019 10-K 16 Apr 2021
2018 -$250M -$114M -84.5% 01 Jan 2018 31 Dec 2018 10-K 27 Mar 2020
2017 -$136M -$126M -1346% 01 Jan 2017 31 Dec 2017 10-K 29 Mar 2019
2016 -$9.37M -$447K -5.01% 01 Jan 2016 31 Dec 2016 10-K 01 Mar 2018
2015 -$8.93M -$6.53M -273% 01 Jan 2015 31 Dec 2015 10-K/A 28 Feb 2018
2014 -$2.4M -$1.6M -202% 01 Jan 2014 31 Dec 2014 10-K/A 28 Feb 2018
2013 -$793K +$2.72M +77.4% 01 Jan 2013 31 Dec 2013 10-K 31 Mar 2015
2012 -$3.51M +$414K +10.5% 01 Jan 2012 31 Dec 2012 10-K 08 Jan 2015
2011 -$3.93M -$1.43M -57.3% 01 Jan 2011 31 Dec 2011 10-K 18 Nov 2014
2010 -$2.5M 01 Jan 2010 31 Dec 2010 10-K 16 Apr 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.